C-reactive protein is a marker of inflammatory response and has been widely investigated in cardiovascular and infectious diseases, especially to monitor therapeutic success. However, its role as a predictor of clinical outcome in critically ill patients remains uncertain and controversial. The objective of this study was to investigate the predictive value of C-reactive protein in critically ill patients.
C-reactive protein (CRP) has long been known as a nonspecific acute phase reactant that can be elevated by up to 10,000-fold during acute responses to serious infection or major tissue damage 1 . The role of this acute phase protein is to facilitate removal of micro-organisms and necrotic tissue by activating cell-mediated cytotoxic cascades 2 . In critically ill patients, a systemic inflammatory response syndrome is the common phenomenon underlying various disease entities. Since plasma CRP levels undergo a rapid and robust rise in response to inflammatory stimuli, it can be employed as a biomarker for detecting the presence of systemic inflammation 3 .
Since its discovery in 1930, CRP has been extensively investigated for its role in detecting infections or predicting outcomes in a variety of clinical settings 4 . The clinical applications of CRP measurement include its use as a diagnostic aid, as a marker of disease severity and as a tool to assess response to therapy. More recently, the role of CRP as a predictor of mortality in critically ill patients has been investigated in many observational studies. These have reported conflicting results: some showed higher plasma CRP concentrations in survivors, whereas others found lower concentrations in survivors. We undertook a meta-analysis to systematically review the published studies investigating the predictive value of CRP in critically ill patients.
METHODS
Meta-analyses of non-randomised observational studies present particular challenges due to inherent biases and differences in study designs. Consequently, we undertook this analysis in accordance with the guidelines of the Meta-analysis of Observational Studies in Epidemiology group 5 .
Data sources
An extensive search of PubMed, the Cochrane clinical trial database and EMBASE (from inception to August 2010) was done to identify relevant clinical studies for our meta-analysis. Search items included "C-reactive protein", "critically ill" and "intensive care unit". References from relevant articles, including review papers, were also reviewed.
Study selection
Two reviewers independently searched the literature and examined relevant studies for assessment of data on mortality and CRP concentrations. A study was considered eligible if it was a clinical observational study performed in an intensive care unit, was prospective in design, compared the plasma CRP concentrations in survivors and non-survivors, and there were no language restrictions on the search. Trials done on infants or neonates were excluded.
Data extraction
The following data were extracted from each study: year of publication, patient population, severity of the illness, study design, number of patients being observed, time points of CRP measurement, duration of follow-up, patient loss during follow-up, important confounders and plasma CRP concentrations (expressed as median and range, or mean and standard deviation). Parameters evaluating the diagnostic value of CRP in mortality including area under the receiver operating characteristic curve, specificity and sensitivity were also extracted. The two reviewers independently extracted data and any disagreement was settled by consensus in meetings with both investigators.
If the study provided medians and interquartile ranges rather than means and standard deviations, we estimated the mean (x) and variance (s 2 ) using the value of median, low and high end of the range according to formulas described by Hozo and colleagues 6 :
x ≈ a m b a m b n
Where m is the median, a is the smallest value (minimum), b is the largest value (maximum), and n is the size of the sample.
Statistical analysis
Statistical analyses were done with Review Manager version 5.0 (Cochrane Collaboration) software. The heterogeneity was explored using the statistic I 2 . Pooled effects of mean difference and 95% confidence interval (CI) was calculated with a random effects model when between-study variance was significant (I 2 >56%), or the fixed effect model when heterogeneity was insignificant.
432 studies were initially searched in PubMed, Cochrane clinical trial database and EMBASE.
407 studies were excluded on the basis of abstract and/or title because they were laboratory studies, review articles, animal studies or irrelevant to the current analysis.
25 studies remained for evaluation through reading the full text. 11 studies excluded because:
1 was retrospective in design; 4 investigated the diagnostic value of CRP in ICU; 6 did not include mortality as the study endpoint or CRP levels of the non-survivors were unavailable;
14 studies were nally included into the meta-analysis. Publication bias was assessed using Egger's test by the funnel plot method, with P <0.05 indicating potential bias.
To explore heterogeneity, we pre-specified subgroup analysis a priori, which was to evaluate whether the mean difference of CRP levels between survivors and non-survivors were different at certain time points we defined as less or greater than 48 hours. Thus we performed meta-analysis separately for early CRP levels (the measurement was taken within 48 hours of disease onset) and late CRP levels (it was measured beyond 48 hours or at intensive care unit [ICU] discharge). Rosenthal's Fail-safe N method was used to test the robustness of the result.
RESULTS
The search originally yielded 432 research reports, of which 407 were excluded on the basis of titles or abstracts because they were laboratory studies, review articles, animal studies or irrelevant to the current analysis. Of the remaining 25 articles, one was a retrospective study, four investigated the diagnostic value of CRP in ICU, and six did not include mortality as the study endpoint or CRP levels of the non-survivors were unavailable ( Figure 1) .
As a result, a total of 1969 patients from 14 studies 7-20 were involved in our review: 483 in the non-survivor group and 1486 in the survivor group. The followup durations varied across the studies, ranging from 14 days to as long as two years. Some studies 9, 17, 18, 20 reported hospital or ICU mortality instead of specific duration of follow-up. Table 1 shows the characteristics of the 14 included studies. All studies enrolled critically ill patients who were treated in ICU. Three studies included general ICU patients 11, 13, 14 ; four included patients with sepsis 10, 16, 17, 20 ; three included patients with ventilator-associated pneumonia 12, 18, 19 ; two included trauma patients 8, 15 ; one included patients with acute respiratory distress syndrome 7 and one study included patients with fever 9 .
With respect to qualitative evaluation of the 14 studies, all were prospective in design, 11 of the studies reported important confounders. Only three studies reported the patient loss during follow-up (Table 2) 8, 13, 19 .
Three studies showed statistically significantly higher CRP levels in survivors compared with non-survivors 7, 15, 17 . Five studies showed statistically significant higher CRP levels in the non-survivors 8, [11] [12] [13] [14] . The CRP levels were not statistically different in the remaining six studies. Due to remarkable heterogeneity across these studies (I 2 =92%), the effect sizes were pooled with the random-effect model. Overall, CRP concentration was greater in non-survivors, but this failed to reach statistical significance. The weighted mean difference in the CRP levels between survivors and non-survivors was 9.15 mg/l (95% CI -6.50 to 24.81) (Figure 2) , and the Z-score for overall effect was 1.15 (P=0.25).
Sensitivity analyses were then performed. The aim was to explore the origin of the heterogeneity. After removal of three studies that had follow-up durations longer than four months 11, 13, 14 , the mean difference was -2.75 mg/l (95% CI -18.52 to 13.01). Thus, longer follow-up cannot explain the heterogeneity. In addition, we removed three studies 9,14,15 that did not report important confounders and found that the mean difference was 9.43 mg/l (95% CI -10.73 to 29.59). The failure to report significant confounders cannot explain the heterogeneity.
We performed a subgroup analyses restricted to early or late CRP levels as between survivors and non-survivors.
Twelve studies reported early (<48 hours of disease onset or admission to ICU) CRP levels [7] [8] [9] [10] 12, [14] [15] [16] [17] [18] [19] [20] , the weighted mean difference in CRP levels between survivors and non-survivors was 1.11 mg/l (95% CI -14.35 to 16.57) (Figure 3) .
Seven studies reported late CRP levels 8, [11] [12] [13] 15, 18, 19 . The CRP level was significantly greater in nonsurvivors with a weighted mean difference of 63.80 mg/l (95% CI 35.67 to 91.93) (Figure 4) .
The Fail-safe N in this subgroup analysis was 291, indicating the robustness of the difference in late CRP concentration between survivors and nonsurvivors.
Publication bias was assessed using a funnel plot ( Figure 5 ). While the distribution of the studies was generally symmetrical in appearance, there were more studies gathered on the top than in the bottom. This indicates that some small studies with wide variance might not have been published.
The diagnostic value of CRP in predicting mortality is shown in Table 3 . The diagnostic power of CRP in predicting mortality as assessed by the area under the receiver operating characteristic curve is low to modest. Because only three studies provided data on the specificity and sensitivity and these had different cut-off values 9, 12, 16 , data on diagnostic value of CRP in predicting mortality cannot be pooled, making analysis impossible.
DISCUSSION
The initial pooled analysis showed no significant difference in CRP levels between survivors and non-survivors. Since the heterogeneity was great (I 2 =92%), we used sensitivity and subgroup analyses to explore the heterogeneity. The sensitivity analyses yielded no explanation for the heterogeneity.
The results of subgroup analysis showed that the mean difference in early CRP levels was more approaching zero than the combined result (9.15 vs 1.11 mg/l), and the mean difference in late CRP level was significantly greater in non-survivors than in survivors. These indicate that at least part of the heterogeneity can be explained by the time of CRP measurement. The CRP level at the early phase of disease onset was not a good predictor of survival, but a persistently elevated CRP level may predict a poor outcome.
The appearance of the funnel plot indicates that some small studies might have been missed. Nüesch and colleagues 21 have studied this effect and concluded that small studies are more likely to distort the result of meta-analysis than large studies.
We believe the missing small studies in our metaanalysis are unlikely to distort the final results and the conclusions we draw from them. Early CRP levels, as demonstrated in our analysis, are not a good predictor of clinical outcome. This can be explained by the following. First, CRP is a marker of systemic inflammation, and can reflect the extent and severity of the inflammation. It is intuitive and rational to hypothesise that severe inflammation, manifested as high CRP level, may predict poor outcome, and this hypothesis has been supported in many clinical observations 22, 23 . However, the elevated CRP level may play a protective role against infection 24 . Thus, the greater plasma CRP level may provide more protection against infectious insults. Suresh and colleagues reported that passive administration of CRP could protect mice from infection by acting on the effector cells of the immune system to enhance cell-mediated cytotoxicity 25 . Therefore, the prognostic value of early plasma CRP level largely depends on whether it can act effectively to suppress the infection, and it is not surprising that the early CRP levels were not significantly different between survivors and nonsurvivors. On the other hand, the late CRP level represents the sustained inflammatory load of the host. The persistent elevation may reflect failure of treatment strategies to control the infection.
Our finding that the late CRP concentration was greater in the non-survivors than in survivors suggests that the persistent inflammatory load is a predictor of poor clinical outcome.
Our meta-analysis may provide novel information regarding the relationship between plasma CRP levels and mortality when the covariate of the time point of CRP measurement is included.
However, limitations of the analysis include the observational nature of the enrolled studies, introducing the prospect of biases.
The potential biases may partly account for unexplained heterogeneity. Another limitation is that only three studies reported patient loss during follow-up, which compromised the quality of these studies. Finally, although most studies attempted to control confounders, the degree to which this was accomplished varied across studies. Therefore, the results of the analysis should be interpreted with caution.
